Congress trades
BridgeBio Pharma, Inc. (BBIO)
About BridgeBio Pharma, Inc.
from the company's filings and listing- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Chief executive
- Neil Kumar
- Employees
- 999
- Listed since
- Jun 27, 2019
- Market value
- $14.9B
- Price to earnings
- -
- Earnings per share
- -$3.56
- Dividend yield
- -
Earnings
6 reported quarters · next on Oct 28, 2026| Quarter | EPS | EPS expected | Revenue | Revenue expected | Result |
|---|---|---|---|---|---|
| Q2 FY2026reported Aug 10, 2026 | -$0.78 | -$0.58 | $243.7M | $220.9M | EPS missRevenue beat |
| Q1 FY2026reported May 7, 2026 | -$0.84 | -$0.68 | $194.5M | $178.1M | EPS missRevenue beat |
| Q4 FY2025reported Feb 24, 2026 | -$1.00 | -$0.71 | $154.2M | $146.8M | EPS missRevenue beat |
| Q3 FY2025reported Oct 29, 2025 | -$0.95 | -$0.88 | $120.7M | $148.2M | EPS missRevenue miss |
| Q2 FY2025reported Aug 5, 2025 | -$0.95 | -$0.83 | $110.6M | $108.1M | EPS missRevenue beat |
| Q1 FY2025reported Apr 29, 2025 | -$0.88 | -$1.00 | $116.6M | $68.4M | EPS beatRevenue beat |
Actual against the consensus estimate at the time. A flag marks a beat or a miss of more than 1.5% either way; inside that band the quarter is in line. A flag marked GAAP compares a GAAP figure the company reported with an adjusted consensus, two different measures, so a one-time gain or charge can move it either way; basis unverified means we could not classify the reported figure. A flag reads n/a only when a number is missing. An estimate is a forecast made by analysts, not a company target.
Executive pay
as filed for 2025 · proxy filed Apr 24, 2026| Executive | Salary | Stock awards | Other | Total |
|---|---|---|---|---|
| Neil Kumar, Ph.D.Chief Executive Officer | $1.0M | $10.6M | $3.3M | $14.9M |
| Thomas Trimarchi, Ph.D.President and Chief Financial Officer | $676K | $4.6M | $554K | $5.8M |
The summary compensation table from the 2025 proxy statement, current executives only. 1 executive who has since left the company is named in that filing and not shown here. Read the filing
Institutional holders
13F positions as of Jun 30, 2026| Holder | Value | Shares | Change | Of company |
|---|---|---|---|---|
| Jupiter Topco LLC | $1.1B | 14,110,278 | +100.0% | 7.21% |
| Kohlberg Kravis Roberts & Co. L.P. | $987.7M | 13,260,971 | 0.0% | 6.77% |
| Farallon Capital Management LLC | $800.1M | 10,743,063 | +14.7% | 5.49% |
| Blackrock, Inc. | $766.2M | 10,287,156 | -27.6% | 5.25% |
| Viking Global Investors LP | $741.0M | 9,949,219 | -16.0% | 5.08% |
| Vanguard Capital Management LLC | $588.3M | 7,898,973 | +1.8% | 4.03% |
| Vanguard Portfolio Management LLC | $570.3M | 7,656,722 | -5.2% | 3.91% |
| Wellington Management Group LLP | $395.4M | 5,308,924 | +113.7% | 2.71% |
| Two Sigma Investments, LP | $351.7M | 4,722,185 | +51.3% | 2.41% |
| Aisling Capital Management LP | $341.8M | 4,589,611 | -9.8% | 2.34% |
| State Street Corp | $330.4M | 4,435,932 | -10.1% | 2.27% |
| UBS Group AG | $287.8M | 3,863,500 | 0.0% | 1.97% |
A 13F reports long US equity positions 45 days after the quarter ends, so these are positions as they stood on Jun 30, 2026. For a manager's whole book see the fund directory.
GetSignal watches Form 4 and STOCK Act filings and pushes each one to your phone as it is published, with the history behind it. Free on iOS and Android.
Congress trades in BBIO
7 disclosures of 7 on record · median 20d of the 45 allowed| Member | Type | Action | Amount disclosed | Since the trade | Trade date | Disclosed | Delay |
|---|---|---|---|---|---|---|---|
| Gilbert Ray Cisneros, Jr. | Stock | Purchase | $1,001 - $15,000 | +17.6%S&P +3.1% · vs S&P 500 +14.5% | May 11, 2026 | Jun 8, 2026 | 28d |
| Gilbert Ray Cisneros, Jr. | Stock | Purchase | $1,001 - $15,000 | +7.3%S&P +7.1% · vs S&P 500 +0.1% | Apr 29, 2026 | May 8, 2026 | 9d |
| Gilbert Ray Cisneros, Jr. | Stock | Purchase | $1,001 - $15,000 | +8.6%S&P +15.5% · vs S&P 500 -6.9% | Mar 19, 2026 | Apr 7, 2026 | 19d |
| Gilbert Ray Cisneros, Jr. | Stock | Purchase | $1,001 - $15,000 | +17.9%S&P +12.0% · vs S&P 500 +5.9% | Mar 3, 2026 | Apr 7, 2026 | 35d |
| Gilbert Ray Cisneros, Jr. | Stock | Purchase | $1,001 - $15,000 | +8.5%S&P +15.2% · vs S&P 500 -6.7% | Mar 18, 2026 | Apr 7, 2026 | 20d |
| Gilbert Ray Cisneros, Jr. | Stock | Purchase | $1,001 - $15,000 | +47.6%S&P +14.0% · vs S&P 500 +33.6% | Sep 22, 2025 | Oct 10, 2025 | 18d |
| Gilbert Ray Cisneros, Jr. | Stock | Purchase | $1,001 - $15,000 | +63.3%S&P +19.7% · vs S&P 500 +43.7% | Aug 8, 2025 | Sep 12, 2025 | 35d |
Since the trade: the stock's move from the trade date to the latest close we hold, as of Sep 10, 2026, an estimate, with the S&P 500 over the same window and the difference against it. The figures describe the stock after the trade, not the member's result: the filing carries a band, not a fill, and a sale keeps the same sign, so a positive figure after a sale means the stock kept rising. An option row carries the underlying stock's move. A row marked n/a has no market price. Not investment advice.
Members of Congress reporting a position
1 member · estimate, as of Sep 10, 20261 member reports a position (estimated). The largest estimated position is in the $50,001 - $100,000 band.
| Member | Party, chamber | Estimated position | Share of their portfolio |
|---|---|---|---|
| Gilbert Ray Cisneros, Jr. | Democrat · House | $50,001 - $100,000 | 0.2% |
Estimate, as of Sep 10, 2026. Each position is modelled from the member's disclosed transactions and annual filings: the midpoint of each disclosed band, moved with the stock's price since the trade. It is a rough estimate of a reported position, not a figure from a filing, which is why it is shown as a band. Share of portfolio sets that estimate against the member's whole estimated public-stock portfolio.
Questions
Which members of Congress have traded BBIO?
Gilbert Ray Cisneros, Jr. disclosed BBIO transactions in the filings shown here.
Which members of Congress hold BBIO?
1 member of Congress reports a position in BBIO in the estimate we hold as of Sep 10, 2026. The largest estimated position belongs to Gilbert Ray Cisneros, Jr.. The estimate is built from disclosed transactions and annual filings, so it is shown as a band rather than a figure from a filing.
How quickly are BBIO trades disclosed?
Congressional disclosures took a median of 20 days, against the 45 the STOCK Act allows.
How to read a STOCK Act filing
WHAT THE FILING ACTUALLY SAYS
Congress rows disclose a value range rather than an exact amount, and the STOCK Act allows up to 45 days to report. Full sourcing and the limits of this data are on the methodology page. A filing is a record of a transaction, not a signal, and nothing here is investment advice.
Data as of Sep 10, 2026.